Discovered in-house by Eisai's Tsukuba Research Laboratories, E7090 is an orally available novel tyrosine kinase inhibitor
that demonstrates selective inhibitory activity against fibroblast growth factor receptors (FGFR) FGFR1, FGFR2 and FGFR3.
In chronic myeloid leukemia patients treated with Imatinib (or other tyrosine kinase inhibitors
) documentation of side effects of therapy from the patients' perspective is useful to evaluate efficacy of treatment and overall clinical benefits of newer treatment options.
Published online, the "Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors
" continues to set standards for the molecular analysis of lung cancers for test results that effectively guide targeted therapy and treatment.
Green et al., "The pan-ErbB receptor tyrosine kinase inhibitor
canertinib promotes apoptosis of malignant melanoma in vitro and displays anti-tumor activity in vivo," Biochemical and Biophysical Research Communications, vol.
Yamamoto et al., "A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor
, in Japanese patients with advanced solid tumors," Cancer Chemotherapy and Pharmacology, vol.
Cortes, "Use of second- and third-generation tyrosine kinase inhibitors
in the treatment of chronic myeloid leukemia: an evolving treatment paradigm," Clinical Lymphoma Myeloma & Leukemia, vol.
Initially, she was treated with tyrosine kinase inhibitors
, including imatinib and nilotinib.
Previous and recent studies have demonstrated both an increased response rate and improved progression free survival with EGFR tyrosine kinase inhibitors
compared with chemotherapy in patients with EGFR mutations.
In contrast to the more common EGFR exon 21 p.L858R point mutation and exon 19 in-frame deletions, which are sensitizing or activating mutations, EGFR exon 20 insertions are generally associated with primary (de novo) resistance exhibited as a lack of or decreased response to tyrosine kinase inhibitors
(TKIs)  (2).
Sunitinib; tyrosine kinase inhibitor
; renal cell carcinoma; hand-foot syndrome.
(2006) EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor
, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib.
* This EGFR-activation mutation is associated with response to EGFR tyrosine kinase inhibitors